Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › How it makes money
How Kiniksa Pharmaceuticals International (KNSA) makes money
Kiniksa Pharmaceuticals International (KNSA) made $286M of revenue in the third quarter 2026 (Q3 2026), +58% from a year earlier. Of every dollar of revenue, 19¢ was left as operating profit, 17¢ was left as net earnings.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $286M | 100.0% |
| Operating profit | $54.2M | 19.0% |
| Income tax | $11.7M | 4.1% |
| Net earnings | $47.3M | 16.6% |
| Operating cash flow | $47.5M | 16.6% |
| Free cash flow | $47.4M | 16.6% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $286M | +58% |
| Q2 2026 | $244M | +55% |
| Q1 2026 | $214M | +56% |
| Q4 2025 | $202M | +65% |
| Q3 2025 | $181M | +61% |
| Q2 2025 | $157M | +44% |
| Q1 2025 | $138M | +72% |
From Kiniksa Pharmaceuticals International's 10-Q filed Oct 27, 2026 (on EDGAR).
Questions
How does Kiniksa Pharmaceuticals International make money?
Kiniksa Pharmaceuticals International (KNSA) made $286M of revenue in the third quarter 2026 (Q3 2026), +58% from a year earlier. Of every dollar of revenue, 19¢ was left as operating profit, 17¢ was left as net earnings.
What is Kiniksa Pharmaceuticals International's profit margin?
Net earnings were $47.3M, 16.6% of revenue, in the third quarter 2026; the operating margin was 19.0%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.